CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 1%

CRISPR Therapeutics AG (NASDAQ:CRSP) was up 1% during trading on Thursday . The company traded as high as $57.98 and last traded at $57.20. Approximately 301,134 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 1,645,584 shares. The stock had previously closed at $56.63.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CRSP. Wells Fargo & Company dropped their target price on CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. Mizuho boosted their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Robert W. Baird increased their target price on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a research report on Thursday, May 9th. Citigroup dropped their price target on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, May 23rd. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $75.71.

CRISPR Therapeutics Price Performance

The company’s 50 day moving average is $56.72 and its 200 day moving average is $64.46.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $25.53 million. The business’s revenue was down 99.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.67) EPS. On average, equities analysts expect that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

Insider Activity

In other news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the sale, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. acquired a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $32,000. Bourgeon Capital Management LLC lifted its holdings in CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after buying an additional 500 shares during the period. Riggs Asset Managment Co. Inc. boosted its position in CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after acquiring an additional 200 shares during the last quarter. Principal Securities Inc. acquired a new stake in CRISPR Therapeutics during the 4th quarter worth about $41,000. Finally, NBC Securities Inc. raised its position in shares of CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after acquiring an additional 438 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.